CQOIVIPBRFSJBE-QFIPXVFZSA-N
C24H24F7N7O2 — CID 137477506
Data last refreshed: (MolForge compound catalog, from PubChem)
About CQOIVIPBRFSJBE-QFIPXVFZSA-N
CQOIVIPBRFSJBE-QFIPXVFZSA-N (PubChem CID 137477506) has the molecular formula C24H24F7N7O2 and a molecular weight of 575.49 g/mol. Its IUPAC name is (2S)-2-[2-fluoro-4-(5,5,5-trifluoropentyl)phenyl]-5-(5-oxo-1H-tetrazol-4-yl)-4-(1-propan-2-ylpyrazol-3-yl)-2-(trifluoromethyl)-1,3-dihydropyridin-6-one.
Molecular Properties
| Compound Name | CQOIVIPBRFSJBE-QFIPXVFZSA-N |
|---|---|
| PubChem CID | 137477506 |
| Molecular Formula | C24H24F7N7O2 |
| Molecular Weight | 575.49 g/mol |
| Exact Mass | 575.19 |
| IUPAC Name | (2S)-2-[2-fluoro-4-(5,5,5-trifluoropentyl)phenyl]-5-(5-oxo-1H-tetrazol-4-yl)-4-(1-propan-2-ylpyrazol-3-yl)-2-(trifluoromethyl)-1,3-dihydropyridin-6-one |
| SMILES | CC(C)n1ccc(C2=C(n3nn[nH]c3=O)C(=O)N[C@@](c3ccc(CCCCC(F)(F)F)cc3F)(C(F)(F)F)C2)n1 |
| InChI | InChI=1S/C24H24F7N7O2/c1-13(2)37-10-8-18(34-37)15-12-22(24(29,30)31,32-20(39)19(15)38-21(40)33-35-36-38)16-7-6-14(11-17(16)25)5-3-4-9-23(26,27)28/h6-8,10-11,13H,3-5,9,12H2,1-2H3,(H,32,39)(H,33,36,40)/t22-/m0/s1 |
| InChIKey | CQOIVIPBRFSJBE-QFIPXVFZSA-N |
| XLogP | 4.50 |
| TPSA | 110.49 Ų |
| H-Bond Donors | 2 |
| H-Bond Acceptors | 7 |
| Rotatable Bonds | 8 |
| Heavy Atoms | 40 |
| Complexity | — |
Lipinski Rule of Five
1 violation
| Rule | Value |
|---|---|
| MW ≤ 500 | 575.49 |
| LogP ≤ 5 | 4.50 |
| H-Bond Donors ≤ 5 | 2 |
| H-Bond Acceptors ≤ 10 | 7 |
Computed Properties (RDKit)
| Structural Alerts | {'alert_name': 'Aliphatic_long_chain', 'substructure': 'N/A'} |
|---|
Frequently Asked Questions
Browse: Molecules A–Z · all molecules A–Z · drugs A–Z · protein targets A–Z.
Sources
- PubChem CID 137477506 — identifiers, structure, computed properties (public domain)
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.